Diabetologie und Stoffwechsel 2019; 14(S 01): S74-S75
DOI: 10.1055/s-0039-1688323
Poster
Insulinwirkung und Fettleber
Georg Thieme Verlag KG Stuttgart · New York

Characteristics of patients with type 1 or type 2 diabetes receiving insulin glargine U300 – an analysis of 7,268 patients based on the DPV and DIVE registries

G van Mark
1   Institut für Pharmakologie und Präventive Medizin, Registries, Cloppenburg, Germany
,
S Lanzinger
2   ZIBMT; Universität Ulm, Institut für Epidemiologie und medizinische Biometrie, Ulm, Germany
,
S Sziegoleit
3   Patienten Praxis Berlin Tempelhof, Berlin, Germany
,
F Putz
4   Praxis für Allgemeinmedizin, Wernberg, Germany
,
M Durmaz
5   Praxis für Innere Medizin, Endokrinologie & Diabetologie, Hof, Germany
,
M Borscheller
6   Krankenhaus Pirmasens, Klinik für Gastroenterologie, Pirmasens, Germany
,
T Danne
7   Kinderkrankenhaus auf der Bult, Diabeteszentrum für Kinder und Jugendliche, Hannover, Germany
,
J Seufert
8   Universitätsklinikum Freiburg, Endokrinologie & Diabetologie, Freiburg, Germany
,
R Holl
9   ZIBMT Universität Ulm, Institut für Epidemiologie und medizinische Biometrie, Ulm, Germany
,
P Bramlage
10   IPPMed, Institut für Pharmakologie und präventive Medizin, Cloppenburg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
07 May 2019 (online)

Also available at
 

Background:

Aim of this analysis was to describe the clinical profile of adult U300 recipients with type-1 (T1DM) or type-2 diabetes (T2DM) and its change over time.

Methods:

The analysis was based on the German DIVE/DPV registries.

Results:

Among 492,323 adult patients, 7,268 with T1 or T2DM received U300.

Patients with T2DM were older (67.3 vs. 47.5 years), had higher BMI (32.4 vs. 25.3 kg/m2), and more cardiovascular morbidities than T1DM. The median HbA1c (8.1% both) and fasting blood glucose (167.6 mg/dl vs. 171.2 mg/dl) values were similar. A history of severe hypoglycemia was much less prevalent among T2DM than T1DM (3.1% vs. 10.6%).

EDITION patients had a similar age and male gender proportion, but longer (T1DM) and shorter (T2DM) diabetes duration and a trend for higher BMI values than in clinical practice. Furthermore, patients had higher HbA1c values in the first (T1 & T2DM) and second (T1DM) year after market launch than in EDITION. Basal insulin doses were comparable between early and late adopters, but lower than in EDITION.

Compared to patients receiving U100 for one year, U300 patients had longer diabetes duration (T1 & T2DM), higher BMI and received higher basal insulin doses (T1 & T2DM) than with U100. While HbA1c was comparable between U300 and U100, the rate of severe hypoglycemia under U300 was reduced in T2DM with or without multiple adjustment.

Conclusion:

The data confirm the clinical efficacy and safety profile documented for U300 in the EDITION studies during the first years of its registration.